Cytosorbents Corp 8-K Summary: Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Cytosorbents Corporation on June 5, 2018. The filing details the voting outcomes for director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
At the record date of April 13, 2018, there were 29,983,134 shares of common stock outstanding. A quorum was established with 24,047,845 shares represented. All three proposals submitted to stockholders were approved:
- Proposal 1 (Election of Directors): Five directors were elected to serve until the 2019 Annual Meeting. Significant broker non-votes (15,660,836 shares) were recorded for all nominees.
- Proposal 2 (Executive Compensation): The advisory vote to approve named executive officer compensation passed with 7,678,801 votes "For" versus 628,638 "Against".
- Proposal 3 (Auditor Ratification): The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the year ending December 31, 2018, was ratified with 23,719,711 votes "For".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of the executive compensation package approved in Proposal 2.
- Confirm the tenure and specific responsibilities of the five newly elected directors.
- Review the full proxy statement for details on the significant number of broker non-votes recorded for the director election.
- Check subsequent filings for the company's financial performance for the period ending December 31, 2018, as this 8-K contains no financial data.